ResMed Inc (STU:RME)
€ 232.3 -1.9 (-0.81%) Market Cap: 34.52 Bil Enterprise Value: 34.92 Bil PE Ratio: 32.70 PB Ratio: 6.98 GF Score: 98/100

Resmed Inc at J.P. Morgan Healthcare Conference (Virtual) Transcript

Jan 10, 2022 / 06:30PM GMT
Release Date Price: €210
David A. Low
J.P. Morgan Chase & Co, Research Division - Research Analyst

Hello, everyone. My name is David Low. I cover healthcare companies for -- the Australian Healthcare companies for J.P. Morgan. Today, we've got Mick Farrell, CEO of ResMed with us. Just before I hand over to Mick, just a reminder that you can ask questions at any time you can submit questions at any time via the website. We'll have a Q&A session after Mick finished his presentation. So thanks very much, Mick. Over to you.

Michael J. Farrell
ResMed Inc. - CEO & Director

Thanks, David, and thank you to everybody joining us here on the virtual J.P. Morgan session here this morning, California time. I'm going to start on Slide 4 of my presentation deck, which is entitled ResMed: The Global Leader in Connected and Digital Health. And I'll move pretty quickly through the document about 20 minutes of presentation, and then we'll open up for 20 minutes of Q&A, where I'll be joined by Rob Douglas, our President and COO; and Dave Pendarvis, our Global Chief Administrative Officer

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot